(en) Andrew X. Zhu, Yoon-Koo Kang, Chia-Jui Yen et Richard S. Finn, « REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. », Journal of Clinical Oncology, vol. 36, no 15_suppl, , p. 4003–4003 (ISSN0732-183X et 1527-7755, DOI10.1200/JCO.2018.36.15_suppl.4003, lire en ligne, consulté le )
(en) Niranjan Venkateswaran, Roy Garcia, M. Carmen Lafita-Navarro et Yi-Heng Hao, « Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis », Nature Communications, vol. 15, no 1, , p. 4266 (ISSN2041-1723, DOI10.1038/s41467-024-47868-3, lire en ligne, consulté le )
(en) Andrew X. Zhu, Yoon-Koo Kang, Chia-Jui Yen et Richard S. Finn, « REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. », Journal of Clinical Oncology, vol. 36, no 15_suppl, , p. 4003–4003 (ISSN0732-183X et 1527-7755, DOI10.1200/JCO.2018.36.15_suppl.4003, lire en ligne, consulté le )
(en) Richard S. Finn, Shukui Qin, Masafumi Ikeda et Peter R. Galle, « Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma », New England Journal of Medicine, vol. 382, no 20, , p. 1894–1905 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa1915745, lire en ligne, consulté le )
(en) Emmanuel Benichou, Bolaji Seffou, Selin Topçu et Ophélie Renoult, « The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolism », Nature Communications, vol. 15, no 1, , p. 1879 (ISSN2041-1723, DOI10.1038/s41467-024-45548-w, lire en ligne, consulté le )
(en) Vinay Kumar, Abul K. Abbas et Jon C. Aster, Robbins and Cotran Pathologic Basis of Disease, Professional Edition E-Book, Elsevier Health Sciences, , 1472 p. (ISBN978-0-323-29635-9, lire en ligne), p. 870–873
(en) Niranjan Venkateswaran, Roy Garcia, M. Carmen Lafita-Navarro et Yi-Heng Hao, « Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis », Nature Communications, vol. 15, no 1, , p. 4266 (ISSN2041-1723, DOI10.1038/s41467-024-47868-3, lire en ligne, consulté le )
(en) Andrew X. Zhu, Yoon-Koo Kang, Chia-Jui Yen et Richard S. Finn, « REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. », Journal of Clinical Oncology, vol. 36, no 15_suppl, , p. 4003–4003 (ISSN0732-183X et 1527-7755, DOI10.1200/JCO.2018.36.15_suppl.4003, lire en ligne, consulté le )
(en) Richard S. Finn, Shukui Qin, Masafumi Ikeda et Peter R. Galle, « Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma », New England Journal of Medicine, vol. 382, no 20, , p. 1894–1905 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa1915745, lire en ligne, consulté le )
(en) Emmanuel Benichou, Bolaji Seffou, Selin Topçu et Ophélie Renoult, « The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolism », Nature Communications, vol. 15, no 1, , p. 1879 (ISSN2041-1723, DOI10.1038/s41467-024-45548-w, lire en ligne, consulté le )
(en) Niranjan Venkateswaran, Roy Garcia, M. Carmen Lafita-Navarro et Yi-Heng Hao, « Tryptophan fuels MYC-dependent liver tumorigenesis through indole 3-pyruvate synthesis », Nature Communications, vol. 15, no 1, , p. 4266 (ISSN2041-1723, DOI10.1038/s41467-024-47868-3, lire en ligne, consulté le )
(en) Emmanuel Benichou, Bolaji Seffou, Selin Topçu et Ophélie Renoult, « The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolism », Nature Communications, vol. 15, no 1, , p. 1879 (ISSN2041-1723, DOI10.1038/s41467-024-45548-w, lire en ligne, consulté le )
(en) Richard S. Finn, Shukui Qin, Masafumi Ikeda et Peter R. Galle, « Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma », New England Journal of Medicine, vol. 382, no 20, , p. 1894–1905 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa1915745, lire en ligne, consulté le )
